Previous research evidence demonstrated that CBX 1/2/3/6/8 is an independent predictor of survival HCC patients (Ning et al., 2018), whereas CBX4 was found to stimulate angiogenesis in HCC via its SUMO E3 ligase activity (Li et al., 2014). Here, CBX4 is linked to hepatocellular carcinoma.